Skip to content

Addiction: all studies

Page 100 of 855: studies 991 to 1,000 of 8,547, newest first. Back to the addiction overview

Research

Psychological and neuropsychological assessment of regular hoasca users.

Comprehensive Psychiatry November 1, 2016 Paulo César Ribeiro Barbosa, Rick J. Strassman, Dartiu Xavier Da Silveira et al. 104 citations

Hoasca (also called ayahuasca) is a N,N-dimethyltryptamine (DMT) - containing psychedelic brew originally used for magico-religious purposes by Amerindian populations of the Amazon Basin. Recently, Brazilian syncretic churches have helped spread the ritual use of hoasca to Western societies. The aim of this study was to evaluate substance use, and neuropsychological and psychological...

fMRI study of neural sensitization to hedonic stimuli in long-term, daily cannabis users.

Human Brain Mapping October 2016 Francesca Filbey, Joseph Dunlop, Ariel Ketcherside et al.

Although there is emergent evidence illustrating neural sensitivity to cannabis cues in cannabis users, the specificity of this effect to cannabis cues as opposed to a generalized hyper-sensitivity to hedonic stimuli has not yet been directly tested. Using fMRI, we presented 53 daily, long-term cannabis users and 68 non-using controls visual and tactile cues for cannabis, a natural reward, and,...

Enhanced discriminative stimulus effects of Δ(9)-THC in the presence of cannabidiol and 8-OH-DPAT in rhesus monkeys.

Drug and Alcohol Dependence August 1, 2016 Lance R Mcmahon

Cannabidiol, a therapeutic with potential serotonin (5-hydroxytryptamine; 5-HT) 5-HT1A receptor agonist activity, is the second most prevalent cannabinoid in Cannabis after Δ(9)-THC. The extent to which cannabidiol modifies the effects of Δ(9)-THC has not been firmly established, especially with respect to abuse-related effects in rhesus monkeys where previously antagonistic interactions have...

Oral noribogaine shows high brain uptake and anti-withdrawal effects not associated with place preference in rodents.

Journal of Psychopharmacology July 1, 2016 Deborah C. Mash, Barbara Ameer, Delphine Prou et al. 29 citations

This study investigated the effects of noribogaine, the principal metabolite of the drug ibogaine, on substance-related disorders. In the first experiment, mice chronically treated with morphine were subjected to naloxone-precipitated withdrawal two hours after oral administration of noribogaine. Oral noribogaine dose dependently decreased the global opiate withdrawal score by up to 88% of...

DOI: 10.1177/0269881116641331 (opens in new tab) Full text (opens in new tab) Cns drugs Blood–brain barrier Conditioned place preference Drug brain penetration +5

Mindfulness meditation–based pain relief: a mechanistic account

Annals of the New York Academy of Sciences June 1, 2016 Fadel Zeidan, David R. Vago 304 citations

Pain is a multidimensional experience that involves interacting sensory, cognitive, and affective factors, rendering the treatment of chronic pain challenging and financially burdensome. Further, the widespread use of opioids to treat chronic pain has led to an opioid epidemic characterized by exponential growth in opioid misuse and addiction. The staggering statistics related to opioid use...

Evaluation of Yoga for Preventing Adolescent Substance Use Risk Factors in a Middle School Setting: A Preliminary Group-Randomized Controlled Trial.

Journal of Youth and Adolescence May 31, 2016 Bethany Butzer, Amanda LoRusso, Sunny H Shin et al.

Adolescence is a key developmental period for preventing substance use initiation, however prevention programs solely providing educational information about the dangers of substance use rarely change adolescent substance use behaviors. Recent research suggests that mind-body practices such as yoga may have beneficial effects on several substance use risk factors, and that these practices may...

Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants

Frontiers in Neuroscience April 19, 2016 Cristina Miliano, Giovanni Serpelloni, Claudia Rimondo et al. 195 citations

New psychoactive substances (NPS) are a heterogeneous and rapidly evolving class of molecules available on the global illicit drug market (e.g smart shops, internet, "dark net") as a substitute for controlled substances. The use of NPS, mainly consumed along with other drugs of abuse and/or alcohol, has resulted in a significantly growing number of mortality and emergency admissions for...

DOI: 10.3389/fnins.2016.00153 (opens in new tab) MDMA Addiction Synthetic cannabinoids Neuropharmacology +5

The users of Novel Psychoactive Substances: Online survey about their characteristics, attitudes and motivations

International Journal of Drug Policy March 23, 2016 Christophe Soussan, Anette Kjellgren 152 citations

BACKGROUND: The increasing number of Novel Psychoactive Substances (NPS) constitutes a challenge for public health agencies and researchers worldwide. Scientific studies about NPS and their users are limited and there is a need to explore the general motivations for NPS use but also to examine if and how the motivations differ between substances from separate effect classes. The aim of the...

Deconstructing the Iboga Alkaloid Skeleton: Potentiation of FGF2-induced Glial Cell Line-Derived Neurotrophic Factor Release by a Novel Compound.

ACS Chemical Biology January 15, 2016 Madalee M Gassaway, Teresa L Jacques, Andrew C Kruegel et al. 23 citations

Modulation of growth factor signaling pathways in the brain represents a new experimental approach to treating neuropsychiatric disorders such as depression, anxiety, and addiction. Neurotrophins and growth factors exert synaptic, neuronal, and circuit level effects on a wide temporal range, which suggests a possibility of rapid and lasting therapeutic effects. Consequently, identification of...

DOI: 10.1021/acschembio.5b00678 (opens in new tab) Full text (opens in new tab) Addiction Neuroprotection Brain protection Neurological protection +22